Signature Estate & Investment Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 40.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,505 shares of the medical research company’s stock after selling 1,009 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $755,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP lifted its position in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. State Street Corp boosted its stake in Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Capital World Investors grew its position in Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after acquiring an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Thermo Fisher Scientific by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after acquiring an additional 26,425 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.
Insider Activity
In related news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $71,191,194.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by insiders.
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the previous year, the company posted $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on TMO. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Barclays raised their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. Finally, HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $619.41.
Read Our Latest Report on Thermo Fisher Scientific
Thermo Fisher Scientific Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
